Press Releases

05.19.2025

Pfizer Enters into Exclusive Licensing Agreement with 3SBio

04.26.2025

Pfizer’s Sasanlimab Combination Significantly Improves Event-Free Survival in BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer

04.23.2025

Pfizer Advances Bold Vision for Future of Cancer Care at the ASCO 2025 Annual Meeting

04.14.2025

Pfizer Provides Update on Oral GLP-1 Receptor Agonist Danuglipron

03.11.2025

Arvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical Trial

02.10.2025

Pfizer and Astellas’ PADCEV® (enfortumab vedotin-ejfv) plus KEYTRUDA® (pembrolizumab) Shows Long-Term Efficacy in First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer (la/mUC)

01.28.2025

Pfizer to Showcase Advancements Across Genitourinary Cancers at ASCO GU Cancers Symposium

01.10.2025

Pfizer’s Sasanlimab in Combination with BCG Improves Event-Free Survival in Patients with BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer

09.14.2024

Pfizer Presents Positive Data from Phase 2 Study of Ponsegromab in Patients with Cancer Cachexia

09.11.2024

Pfizer Highlights Diverse Oncology Portfolio and Combination Approaches at ESMO 2024

07.24.2024

Pfizer Announces Positive Topline Results From Phase 3 Study of Hemophilia A Gene Therapy Candidate

07.11.2024

Pfizer Advances Development of Once-Daily Formulation of Oral GLP-1 Receptor Agonist Danuglipron